Evolving Treatment Landscape and Future Directions: Front-Line HER2-Targeted Therapy and Individualized Selection

In this final episode, Dr. Doroshow examines how HER2-mutant non-small cell lung cancer treatment will evolve over the next two years, then synthesizes key takeaways from Sandra's case. She reflects on pre-2026 challenges when she told patients they had targetable genetic alterations but needed to wait until progression on first-line chemo-immunotherapy to access targeted therapy, a message that didn't resonate well with patients or families.

This changed with Food and Drug Administration accelerated approval of zongertinib for front-line use in late February 2026. Dr. Doroshow notes phase 3 trials comparing zongertinib, sevabertinib, and trastuzumab deruxtecan against chemo-immunotherapy standard are ongoing, and she anticipates multiple front-line HER2-directed options becoming available within several years.

Looking ahead, Dr. Doroshow emphasizes selection will be driven by individualized patient factors rather than one-size-fits-all approaches. Distinct toxicity profiles remain clinically relevant: chemotherapy-related side effects and interstitial lung disease risk with trastuzumab deruxtecan versus tyrosine kinase inhibitor toxicities. Her message emphasizes individualized care: knowing each patient, understanding their priorities, and selecting therapies aligning with their values.

In closing, Dr. Doroshow synthesizes Sandra's case themes. Second-line treatment decisions extend beyond identifying HER2 mutation, requiring integration of multiple factors. Incomplete upfront next-generation sequencing remains a significant barrier altering treatment trajectory. Financial toxicity emerges as a primary treatment selection driver, and addressing cost barriers through patient assistance programs represents essential comprehensive care.

Thank you for watching this Case-Based Peer Perspectives on second-line treatment selection in HER2-mutant NSCLC. Please subscribe to our e-newsletter for information on upcoming video series and continued education in precision oncology.